30,101 Shares in Elanco Animal Health Incorporated $ELAN Acquired by Aigen Investment Management LP

Aigen Investment Management LP bought a new position in Elanco Animal Health Incorporated (NYSE:ELAN) during the fourth quarter, Holdings Channel.com reports. The fund bought 30,101 shares of the company’s stock, valued at approximately $681,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Kestra Advisory Services LLC bought a new stake in shares of Elanco Animal Health in the 4th quarter worth approximately $168,000. CreativeOne Wealth LLC bought a new stake in shares of Elanco Animal Health in the 4th quarter worth approximately $1,260,000. Quartz Partners LLC raised its holdings in shares of Elanco Animal Health by 5.7% in the 4th quarter. Quartz Partners LLC now owns 74,774 shares of the company’s stock worth $1,692,000 after purchasing an additional 4,055 shares in the last quarter. Maverick Capital Ltd. raised its holdings in shares of Elanco Animal Health by 240.4% in the 4th quarter. Maverick Capital Ltd. now owns 106,593 shares of the company’s stock worth $2,412,000 after purchasing an additional 75,278 shares in the last quarter. Finally, Bridgewater Associates LP bought a new stake in shares of Elanco Animal Health in the 4th quarter worth approximately $501,000. 97.48% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Elanco Animal Health

In related news, insider Rajeev A. Modi bought 4,911 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the purchase, the insider directly owned 160,812 shares in the company, valued at $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jeffrey N. Simmons bought 4,971 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were bought at an average price of $20.09 per share, with a total value of $99,867.39. Following the completion of the purchase, the chief executive officer owned 171,971 shares in the company, valued at approximately $3,454,897.39. The trade was a 2.98% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 1.14% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings lowered shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. JPMorgan Chase & Co. boosted their price target on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Citigroup boosted their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, May 7th. KeyCorp boosted their price target on shares of Elanco Animal Health from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Finally, Leerink Partners boosted their price target on shares of Elanco Animal Health from $26.00 to $30.00 and gave the company an “outperform” rating in a report on Tuesday, February 24th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Elanco Animal Health has an average rating of “Moderate Buy” and a consensus target price of $28.20.

Elanco Animal Health Stock Performance

ELAN stock opened at $24.19 on Monday. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. The company has a market capitalization of $12.08 billion, a price-to-earnings ratio of -48.39, a P/E/G ratio of 1.58 and a beta of 1.69. Elanco Animal Health Incorporated has a 12 month low of $13.15 and a 12 month high of $27.72. The firm has a 50 day moving average of $22.90 and a two-hundred day moving average of $23.47.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, May 6th. The company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.34 by $0.06. The company had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.28 billion. Elanco Animal Health had a negative net margin of 4.95% and a positive return on equity of 7.42%. The company’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.37 earnings per share. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, equities analysts anticipate that Elanco Animal Health Incorporated will post 1.11 EPS for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.